# Irinotecan

## Irino IV infusion 100mg/5mL

| TAH Drug Code      | [IIRI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IIRI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Refractory colorectal malignancies , 1st line treatment of metastatic colorectal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Monotherapy (for previously treated patient): [Colorectal cancer, metastatic] 350 mg/m2 as a single agent infused over 90 minutes once every 3 weeks. [Gastric cancer, metastatic or locally advanced] 150 mg/m2 as a single agent infused over 30-90 minutes on days 1 and 15 of a 4-week treatment cycle. Combination therapy (for treatment naive patients):180 mg/m2 over 90 minutes on days 1, 15, and 29 in combination with infusional leucovorin and bolus/infusion fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin). |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Known hypersensitivity to irinotecan or any component of the formulation. Coadministraton with azole antifungals (ketoconazole, fluconazole, itraconazole); patients with hereditary fructose intolerance                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Neutropenia, anemia, thrombocytopenia; acute diarrhoea, sweating, hypersalivation, abdominal cramps, lachrymation, miosis, weakness; nausea, vomiting, alopecia and skin reactions; cardiovascular toxicity. Potentially Fatal: Fatal sepsis due to myelosuppression; severe, chronic diarrhoea                                                                                                                                                                                                                                                                                                     |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/irinotecan-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

